Suppr超能文献

肝纤维化的非侵入性检测:超顺磁性氧化铁颗粒增强磁共振成像是否为一项有价值的技术?

Non-invasive detection of liver fibrosis: Is superparamagnetic iron oxide particle-enhanced MR imaging a contributive technique?

作者信息

Lucidarme Olivier, Baleston Florence, Cadi Mehdi, Bellin Marie-France, Charlotte Frédéric, Ratziu Vlad, Grenier Philippe A

机构信息

Department of Radiology, Université Paris VI, Hôpital de la Pitié-Salpêtrière Assistance Publique-Hôpitaux de Paris, 47, boulevard de l'Hôpital, 75651 Paris Cedex 13, France.

出版信息

Eur Radiol. 2003 Mar;13(3):467-74. doi: 10.1007/s00330-002-1667-9. Epub 2002 Sep 13.

Abstract

The purpose of our study was to evaluate the ability of superparamagnetic iron oxide (SPIO)-enhanced MR imaging to detect liver fibrosis in patients with chronic liver disease and to compare the findings with histopathological data. Sixty-seven patients with chronic hepatitis ( n=58) or focal nodular hyperplasia (FNH; n=9) were studied using a 1.5-T MR system. The protocol included proton density-weighted, T2-weighted spin-echo (SE) and fast SE (FSE) sequences before and after SPIO administration and T2*-weighted gradient-recalled-echo (GRE) sequences after SPIO. Pre- and post-contrast T2-weighted and T2*-weighted sequences were retrospectively evaluated by three independent observers for evidence of non-tumor hypersignal intensities. Three liver patterns were considered: thick reticulations; thin reticulations; and/or multiple areas of hypersignal intensities. Unenhanced or enhanced patterns were compared with histopathological specimens, which had been obtained by percutaneous biopsy of the right lobe within a maximum of 12 months of MR examination. Liver fibrosis was histologically graded using a five-level scale (F0-F4), according to the METAVIR classification. Histopathology demonstrated significant fibrosis (F2-F4) in 57 patients, non-significant fibrosis in 1 patient (F1), and normal liver surrounding FNH in 9 patients (F0). After SPIO administration, at least one pattern of non-tumor hypersignal intensities was seen in 43 (76%) of the 57 patients with F>/=2 with good agreement (kappa=0.68) compared with 2 (20%) of the 10 F0/1 patients ( p<0.01). Attenuated non-homogeneous liver-signal intensities with persistent thick reticulations, thin reticulations, or multiple areas of hypersignals were observed in, respectively, 30, 52, and 56% of patients with F>/=2 with moderate agreement (kappa=0.51). Before SPIO, MR images were positive in 21 of 57 (37%) F>/=2 and zero F0/1 patients. Post-contrast proton-density-weighted and T2*-weighted GRE were the most sensitive sequences for detecting non-tumor hypersignal intensities. In patients with chronic liver diseases, SPIO-enhanced MR imaging exhibits non-tumor hypersignal intensities indicative of liver fibrosis by decreasing the signal from the non-fibrotic areas where Kupffer cells are present.

摘要

我们研究的目的是评估超顺磁性氧化铁(SPIO)增强磁共振成像检测慢性肝病患者肝纤维化的能力,并将结果与组织病理学数据进行比较。使用1.5-T磁共振系统对67例慢性肝炎患者(n = 58)或局灶性结节性增生(FNH;n = 9)进行了研究。该方案包括SPIO给药前后的质子密度加权、T2加权自旋回波(SE)和快速SE(FSE)序列以及SPIO给药后的T2 *加权梯度回波(GRE)序列。三位独立观察者对对比前和对比后的T2加权和T2 *加权序列进行回顾性评估,以寻找非肿瘤高信号强度的证据。考虑了三种肝脏模式:粗网状;细网状;和/或多个高信号强度区域。将未增强或增强模式与组织病理学标本进行比较,这些标本是在磁共振检查最多12个月内通过右叶经皮活检获得的。根据METAVIR分类,使用五级量表(F0-F4)对肝纤维化进行组织学分级。组织病理学显示,57例患者有显著纤维化(F2-F4),1例患者无显著纤维化(F1),9例FNH周围肝脏正常(F0)。在SPIO给药后,57例F≥2的患者中有43例(76%)出现至少一种非肿瘤高信号强度模式,与10例F0/1患者中的2例(20%)相比,一致性良好(kappa = 0.68)(p<0.01)。在F≥2的患者中,分别有30%、52%和56%观察到伴有持续粗网状、细网状或多个高信号区域的减弱的不均匀肝脏信号强度,一致性中等(kappa = 0.51)。在SPIO给药前,57例F≥2的患者中有21例(37%)磁共振图像呈阳性,F0/1患者为零例。对比后质子密度加权和T2 *加权GRE序列是检测非肿瘤高信号强度最敏感的序列。在慢性肝病患者中,SPIO增强磁共振成像通过降低存在库普弗细胞的非纤维化区域的信号,表现出指示肝纤维化的非肿瘤高信号强度。

相似文献

2
Colorectal hepatic metastases: detection with SPIO-enhanced breath-hold MR imaging--comparison of optimized sequences.
Radiology. 2003 Sep;228(3):709-18. doi: 10.1148/radiol.2283020376. Epub 2003 Jul 29.
5
Hepatic metastases: diffusion-weighted sensitivity-encoding versus SPIO-enhanced MR imaging.
Radiology. 2006 Apr;239(1):122-30. doi: 10.1148/radiol.2383041384. Epub 2006 Feb 21.
10

引用本文的文献

1
Advances in magnetic particle imaging and perspectives on liver imaging.
ILIVER. 2022 Nov 8;1(4):237-244. doi: 10.1016/j.iliver.2022.10.003. eCollection 2022 Dec.
2
Molecular Imaging for Early-Stage Disease Diagnosis.
Adv Exp Med Biol. 2023;1199:39-58. doi: 10.1007/978-981-32-9902-3_3.
3
Advances in functional and molecular MRI technologies in chronic liver diseases.
J Hepatol. 2020 Nov;73(5):1241-1254. doi: 10.1016/j.jhep.2020.06.020. Epub 2020 Jun 22.
4
Synergistic MicroRNA Therapy in Liver Fibrotic Rat Using MRI-Visible Nanocarrier Targeting Hepatic Stellate Cells.
Adv Sci (Weinh). 2019 Jan 15;6(5):1801809. doi: 10.1002/advs.201801809. eCollection 2019 Mar 6.
5
Non-invasive diagnosis of liver fibrosis and cirrhosis.
World J Gastroenterol. 2015 Nov 7;21(41):11567-83. doi: 10.3748/wjg.v21.i41.11567.
6
Histogram analysis of hepatobiliary phase MR imaging as a quantitative value for liver cirrhosis: preliminary observations.
Yonsei Med J. 2014 May;55(3):651-9. doi: 10.3349/ymj.2014.55.3.651. Epub 2014 Apr 1.
8
Noninvasive classification of hepatic fibrosis based on texture parameters from double contrast-enhanced magnetic resonance images.
J Magn Reson Imaging. 2012 Nov;36(5):1154-61. doi: 10.1002/jmri.23759. Epub 2012 Jul 31.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验